A recent case series has highlighted the potential of nanosecond Retinal Rejuvenation Therapy (2RT) laser treatment for patients suffering from Doyne Honeycomb Retinal Dystrophy (DHRD), also known as Malattia Leventinese. The long-term structural and functional assessment provides encouraging evidence that this non-thermal laser approach could offer a new therapeutic avenue for a condition that currently lacks effective treatments.
DHRD is an autosomal dominant macular dystrophy caused by a specific mutation in the EFEMP1 gene. It is characterized by the accumulation of drusen in the macula, leading to progressive visual impairment. Traditional continuous-wave lasers have been used in the past to reduce drusen, but they often carry the risk of thermal damage to the retina and subsequent complications.
The nanosecond 2RT laser, however, delivers ultra-short pulses of energy that specifically target the retinal pigment epithelium (RPE) without causing collateral thermal damage to the overlying neurosensory retina. The recent study demonstrated that patients treated with the 2RT laser experienced functional improvements and a reduction in drusen volume over a long-term follow-up period.
While these findings are based on a case series and require validation through larger, randomized controlled trials, they represent a significant step forward. The ability to safely reduce drusen burden and improve retinal function could dramatically alter the prognosis for individuals with Malattia Leventinese.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.